Emtricitabine

Caitlin Soto, PharmD, BCIDP, Janessa Smith, Smith
Pediatric Dosing Author: Alice Hsu Jenh Hsu, Pharm.D.

INDICATIONS

FDA

  • Treatment of HIV-1 infection in combination with other antiretroviral agents
  • Pre-exposure prophylaxis (PrEP) as a component of FDA-approved FTC/TDF or FTC/TAF fixed-dose combinations.
    • FTC/TDF: adults and adolescents weighing ≥35 kg with potential sexual or injection-drug exposure.
    • FTC/TAF: adults and adolescents weighing ≥35 kg with potential sexual exposure, excluding those likely to acquire HIV through receptive vaginal sex.

NON-FDA APPROVED USES

  • Treatment of hepatitis B in HIV-HBV co-infected patients as part of a fully suppressive ART regimen containing TAF or TDF plus FTC
    • FTC should not be used as the sole HBV-active drug because HBV resistance emerges readily.
  • Post-exposure prophylaxis (PEP) in combination with other agents.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.